Evidence map›Paper›PMID 37418300›Full record

ArticleMicrobiology (Reading, England)2023

Decolonizing drug-resistant

Jessica H Forsyth, Natalie L Barron, Lucy Scott, Bridget N J Watson, Matthew A W Chisnall, Sean Meaden, Stineke van Houte, Ben Raymond

Abstract read
In one paragraph

Article in Microbiology (Reading, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Microbiotherapy: an emerging adjunct for burn wound healing.Frontiers in cellular and infection microbiology · 2026
    Review
  5. Bacteriophage-mediated reduction of uropathogenicbioRxiv : the preprint server for biology · 2025
    Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Gut residentmedRxiv : the preprint server for health sciences · 2024
    Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jessica H ForsythCentre for Ecology and Conservation, University of Exeter, Penryn, TR10 9FE, UK.
Natalie L BarronCentre for Ecology and Conservation, University of Exeter, Penryn, TR10 9FE, UK.
Lucy ScottCentre for Ecology and Conservation, University of Exeter, Penryn, TR10 9FE, UK.
Bridget N J WatsonCentre for Ecology and Conservation, University of Exeter, Penryn, TR10 9FE, UK.
Matthew A W ChisnallCentre for Ecology and Conservation, University of Exeter, Penryn, TR10 9FE, UK.
Sean MeadenCentre for Ecology and Conservation, University of Exeter, Penryn, TR10 9FE, UK.
Stineke van HouteCentre for Ecology and Conservation, University of Exeter, Penryn, TR10 9FE, UK.
Ben RaymondCentre for Ecology and Conservation, University of Exeter, Penryn, TR10 9FE, UK.

Funding

Biotechnology and Biological Sciences Research Council BB/R010781/1Biotechnology and Biological Sciences Research Council BB/S017674/1Medical Research Council MR/N013824/1
6 · The paper itself

Abstract

Widespread antibiotic resistance in commensal bacteria creates a persistent challenge for human health. Resident drug-resistant microbes can prevent clinical interventions, colonize wounds post-surgery, pass resistance traits to pathogens or move to more harmful niches following routine interventions such as catheterization. Accelerating the removal of resistant bacteria or actively decolonizing particular lineages from hosts could therefore have a number of long-term benefits. However, removing resident bacteria via competition with probiotics, for example, poses a number of ecological challenges. Resident microbes are likely to have physiological and numerical advantages and competition based on bacteriocins or other secreted antagonists is expected to give advantages to the dominant partner, via positive frequency dependence. Since a narrow range of

Indexed as

BacteriophagesEscherichia coli InfectionsProbioticsAnti-Bacterial AgentsDrug Resistance, Multiple, BacterialEscherichia coliHumansAnti-Bacterial AgentsAMRantagonistic competitiondrug resistancefrequency dependencephage therapyresistance management

Identifiers

PMID37418300
PMCPMC10433417

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.